TY - JOUR
T1 - Immune checkpoint blockade
T2 - The hope for immunotherapy as a treatment of lung cancer?
AU - Brahmer, Julie R.
PY - 2014/2
Y1 - 2014/2
N2 - Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.
AB - Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.
UR - http://www.scopus.com/inward/record.url?scp=84894499071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894499071&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2013.12.014
DO - 10.1053/j.seminoncol.2013.12.014
M3 - Article
C2 - 24565586
AN - SCOPUS:84894499071
SN - 0093-7754
VL - 41
SP - 126
EP - 132
JO - Seminars in oncology
JF - Seminars in oncology
IS - 1
ER -